Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 4/2007

01-04-2007 | Letter to the Editor

Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation

Authors: Jeroen S. Goede, Benjamin Misselwitz, Christian Taverna, Urs Schanz, Angela Dispenzieri, Yvonne Hummel, Ralph M. Trüeb, Jörg Fehr

Published in: Annals of Hematology | Issue 4/2007

Login to get access

Abstract

Paraproteinemia can be complicated by necrobiotic xanthogranuloma. Therapeutic options for this progressive disease are limited, and there is no agreement on a single best strategy. We report the case of a patient with a massive periorbital infiltration narrowing the palpebral fissure and blinding the patient. Conventional myeloma therapy had only limited benefit in our patient. However, he was successfully treated with high-dose chemotherapy followed by autologous stem cell transplantation, rendering the patient free of symptoms. This is the first report of autologous stem cell transplantation in a patient with necrobiotic xanthogranuloma.
Literature
1.
Kossard S, Winkelmann RK (1980) Necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol 3(3):257–270PubMedCrossRef
2.
Mehregan DA, Winkelmann RK, Wilson Jones E (1992) Necrobiotic xanthogranuloma. Arch Dermatol 128(1):94–100PubMedCrossRef
3.
Ugurlu S, Bartley GB, Gibson LE (2000) Necrobiotic xanthogranuloma: long-term outcome of ocular and systemic involvement. Am J Ophthalmol 129(5):651–657PubMedCrossRef
4.
Chave TA, Chowdhury MM, Holt PJ (2002) Recalcitrant necrobiotic xanthogranuloma responding to pulsed high-dose oral dexamethasone plus maintenance therapy with oral prednisone. Br J Dermatol 144(1):158–161CrossRef
5.
Criado PR, Vasconcellos C, Pegas JR, Lopes LF, Ramos CF, Tebcherani AJ et al (2002) Necrobiotic xanthogranuloma with lambda paraproteinemia: case report of successful treatment with melphalan and prednisone. J Derm Treat 13(2):87–89CrossRef
6.
Georgiou S, Monastirli A, Kapranos N, Pasmatzi E, Sakkis T, Tsambaos D (1999) Interferon alpha-2a monotherapy for necrobiotic xanthogranuloma. Acta Derm Venereol 79(6):484–485PubMedCrossRef
7.
Finelli LG, Ratz JL (1987) Plasmapheresis, a treatment modality for necrobiotic xanthogranuloma. J Am Acad Dermatol 17(2):351–354PubMedCrossRef
8.
Schaffner A, Augustiny N, Otto RC, Fehr J (1985) The hypersplenic spleen. A contractile reservoir of granulocytes and platelets. Arch Intern Med 145(4):651–654PubMedCrossRef
9.
Bullock JD, Bartley GB, Campbell RJ, Yanes B, Connelly PJ, Funkhouser JW (1986) Necrobiotic xanthogranuloma with paraproteinemia: case report and a pathogenetic theory. Ophthalmology 93(9):1233–1236PubMed
10.
Rappersberger K, Wrba F, Heinz R, Zonzits E, Hönigsmann H (1989) Necrobiotic xanthogranuloma in paraproteinemia. Hautarzt 40(6):358–363PubMed
11.
Char DH, LeBoit PE, Ljung BM, Wara W (1987) Radiation therapy for ocular necrobiotic xanthogranuloma. Arch Ophthalmol 105(2):174–175PubMed
12.
Schaudig U, Al-Samir K (2004) Upper and lower eyelid reconstruction for severe disfiguring necrobiotic xanthogranuloma. Orbit 23(1):65–76PubMedCrossRef
Metadata
Title
Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation
Authors
Jeroen S. Goede
Benjamin Misselwitz
Christian Taverna
Urs Schanz
Angela Dispenzieri
Yvonne Hummel
Ralph M. Trüeb
Jörg Fehr
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 4/2007
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-006-0231-0

Other articles of this Issue 4/2007

Annals of Hematology 4/2007 Go to the issue

Letter to the Editor

Hyperleukocytosis in patients with leukemic follicular lymphoma

Letter to the Editor

Late onset of bortezomib-associated cutaneous reaction following herpes zoster

Original Article

Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia

Letter to the Editor

An unusual case of pancytopenia associated with Sheehan’s syndrome

Original Article

Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients

Original Article

Teaching hematology to second year medical students: results of a national survey of hematology course directors
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits